Alnylam Pharmaceuticals, Inc.
ALNY
$251.56
$8.953.69%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 2.25B | 2.09B | 2.34B | 2.00B | 1.83B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.25B | 2.09B | 2.34B | 2.00B | 1.83B |
| Cost of Revenue | 323.37M | 306.41M | 304.82M | 321.51M | 310.41M |
| Gross Profit | 1.92B | 1.79B | 2.04B | 1.68B | 1.52B |
| SG&A Expenses | 975.53M | 878.31M | 856.49M | 822.78M | 795.65M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.43B | 2.28B | 2.24B | 2.18B | 2.11B |
| Operating Income | -176.89M | -188.13M | 102.64M | -175.80M | -282.18M |
| Income Before Tax | -377.38M | -321.10M | -61.70M | -324.74M | -433.52M |
| Income Tax Expenses | -99.22M | 11.16M | 11.24M | 7.33M | 6.73M |
| Earnings from Continuing Operations | -278.16 | -332.26 | -72.94 | -332.08 | -440.24 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -278.16M | -332.26M | -72.94M | -332.08M | -440.24M |
| EBIT | -176.89M | -188.13M | 102.64M | -175.80M | -282.18M |
| EBITDA | -120.22M | -132.15M | 157.97M | -122.30M | -228.12M |
| EPS Basic | -2.17 | -2.62 | -0.57 | -2.65 | -3.53 |
| Normalized Basic EPS | -1.82 | -1.57 | -0.22 | -1.55 | -2.09 |
| EPS Diluted | -2.17 | -2.62 | -0.60 | -2.68 | -3.56 |
| Normalized Diluted EPS | -1.82 | -1.57 | -0.26 | -1.59 | -2.13 |
| Average Basic Shares Outstanding | 510.58M | 507.07M | 503.70M | 501.63M | 499.60M |
| Average Diluted Shares Outstanding | 510.58M | 507.07M | 509.82M | 507.75M | 505.72M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |